|0.3151||-0.0053||-1.65%||Vol 191.27K||1Y Perf -59.94%|
|Jan 27th, 2023 16:00 DELAYED|
|- -||0.00 1.56%|
|Target Price||3.25||Analyst Rating||Strong Buy 1.00|
|Potential %||931.42||Finscreener Ranking||★★★★★ 70.06|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 62.04|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★+ 65.63|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||2.34||Earnings Rating||Strong Buy|
|Market Cap||7.76M||Earnings Date||10th Nov 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.19|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||132.51K|
|Avg. Monthly Volume||151.95K|
|Avg. Quarterly Volume||177.90K|
Arcadia Biosciences Inc. (NASDAQ: RKDA) stock closed at 0.3151 per share at the end of the most recent trading day (a -1.65% change compared to the prior day closing price) with a volume of 191.27K shares and market capitalization of 7.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Agriculture industry, Basic Materials sector and employs 61 people. Arcadia Biosciences Inc. CEO is Matthew T. Plavan.
The one-year performance of Arcadia Biosciences Inc. stock is -59.94%, while year-to-date (YTD) performance is 16.27%. RKDA stock has a five-year performance of -95.05%. Its 52-week range is between 0.259 and 2.66, which gives RKDA stock a 52-week price range ratio of 2.34%
Arcadia Biosciences Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.32, a price-to-sale (PS) ratio of 0.92, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.23%, a ROC of -57.52% and a ROE of -69.41%. The company’s profit margin is 20.09%, its EBITDA margin is -83.10%, and its revenue ttm is $8.96 Million , which makes it $0.36 revenue per share.
Of the last four earnings reports from Arcadia Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Arcadia Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arcadia Biosciences Inc. is Strong Buy (1), with a target price of $3.25, which is +931.42% compared to the current price. The earnings rating for Arcadia Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcadia Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcadia Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.20, ATR14 : 0.04, CCI20 : -27.71, Chaikin Money Flow : -0.20, MACD : 0.00, Money Flow Index : 55.07, ROC : -10.79, RSI : 46.97, STOCH (14,3) : 12.36, STOCH RSI : 0.00, UO : 32.55, Williams %R : -87.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcadia Biosciences Inc. in the last 12-months were: Pamela Haley (Buy at a value of $490)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.